Annexin Pharmaceuticals
15.55 SEK
-2.20 %
Less than 1K followers
ANNX
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
-2.20 %
+20.54 %
-2.81 %
-21.46 %
-44.06 %
-44.66 %
-74.37 %
-84.85 %
-95.14 %
Annexin Pharmaceuticals is a biotechnology company developing the drug candidate ANXV, based on the protein Annexin A5, for the treatment of diseases such as vascular damage, inflammation and certain cancers. The company's partners are healthcare providers and biopharmaceutical companies and the business is aimed at global markets through research and licensing collaborations. The company was founded in 2014 and is headquartered in Stockholm, Sweden.
Read moreMarket cap
109.77M SEK
Turnover
24.02K SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
Revenue
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
12.5
2026
General meeting '26
16.7
2026
Interim report Q2'26
22.10
2026
Interim report Q3'26
All
Press releases
ShowingAll content types
Annexin accelerates patient recruitment – five patients treated
Annexin secures financing through bridge loan facility and plans a rights issue of approximately SEK 20 million during the summer of 2026
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools